WO2023248978A1 - 臨床試験支援方法、及び臨床試験支援システム - Google Patents
臨床試験支援方法、及び臨床試験支援システム Download PDFInfo
- Publication number
- WO2023248978A1 WO2023248978A1 PCT/JP2023/022600 JP2023022600W WO2023248978A1 WO 2023248978 A1 WO2023248978 A1 WO 2023248978A1 JP 2023022600 W JP2023022600 W JP 2023022600W WO 2023248978 A1 WO2023248978 A1 WO 2023248978A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- clinical trial
- information
- patient
- patients
- clinical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Definitions
- the present invention relates to a method for supporting clinical trials, and in particular to a clinical trial design, a method for screening patients who meet eligibility criteria for trial participants, and a clinical trial support system.
- subjects for clinical trials and clinical trials have mainly been recruited from patients admitted to or visiting the medical institution where the trial is being conducted. Specifically, this is done by a doctor selecting potential target patients from among the patients he/she treats, or by a clinical trial coordinator searching for target patients while checking the contents of medical records.
- the patient may be selected from a group of patients registered as a patient cohort.
- the eligibility and exclusion conditions of the trial protocol which are summarized in several pages to about 10 pages, are compared with clinical data to determine whether the patient meets the conditions for the clinical trial. Patients are selected.
- Eligibility criteria for clinical trials are determined in detail, and determination of eligibility requires precision and rigor, so it takes a great deal of time to confirm whether each patient meets the eligibility criteria. Therefore, it has become a problem that it requires a great deal of effort for doctors and clinical trial coordinators to select clinical trial candidates from patients visiting the hospital or being hospitalized.
- Patent Documents 1 to 5 disclose methods for screening patients who meet eligibility criteria for clinical trials and methods for formulating eligibility criteria.
- Patent Document 1 discloses a method of screening patients suitable for a clinical trial by comparing prescriptions and dispensing information prescribed to patients with information indicating eligibility criteria for a clinical trial. With this method, if information identifying the medical institution that created the prescription is included, it is possible to estimate how many patients each medical institution has.
- Patent Document 2 discloses a system that includes an input means for a doctor to input data on test candidates, a test subject selection means for verifying the data and selecting a test subject, and an information processing means for collecting data on the selected test subjects. Disclosed.
- Patent Document 3 attempts to identify the number of potential researchers based on disease-related expertise, track record in clinical trials, etc., and estimate the number of subjects in clinical trials.
- Patent Document 4 discloses a system and method for formulating inclusion (eligibility criteria)/exclusion criteria based on quantitative analysis in order to develop a viable clinical trial implementation plan.
- Patent Document 5 discloses a matching device that searches for a clinical trial that suits a patient based on patient information.
- Patent Document 1 is prescription and dispensing information, it is only possible to guess the disease name, and it is not possible to obtain any information about the treatments the patient has received, such as surgery. However, the information is incomplete and does not reduce the burden on doctors and coordinators who screen patients.
- the invention described in Patent Document 2 requires input of data regarding test candidates provided by a doctor, and cannot reduce the doctor's labor in patient screening.
- the invention described in Patent Document 3 attempts to ascertain the number of target patients based on the doctor's expertise. Although it is possible to roughly estimate the number of trial candidates, patient selection depends on the doctor's memory, and it is not possible to accurately determine the number of trial candidates.
- the invention described in Patent Document 4 selects parameters from many parameters, including type/stage of disease/disorder, age, gender, and phase of clinical trials, in order to perform quantitative analysis to formulate a feasible implementation plan. and needs to be analyzed.
- the selection of parameters is not necessarily unambiguous, and it is not possible to select the optimal eligibility criteria and verify whether it is possible to formulate an implementation plan.
- the invention described in Patent Document 5 is a system that searches for matching clinical trials for patients, which reduces the effort required for pharmaceutical companies to secure test subjects and for doctors to determine whether patients meet eligibility criteria. There is no system in place for this purpose. Furthermore, even when searching for a clinical trial suitable for a patient, it is necessary to register patient information because it is not linked to a database in which patient information is stored, which requires considerable effort.
- the present invention relates to a method and system for screening candidates for the following clinical trials and clinical trials.
- a method for screening clinical trial candidates which is characterized by searching a database using search words and extracting qualified candidates. By converting clinical trial eligibility and exclusion conditions into search terms and screening them, clinical trial candidates can be narrowed down quickly and efficiently.
- a system for screening clinical trial candidates which includes a server computer that stores patient information, an electronic medical record system with a data warehouse, a terminal for inputting patient information from each clinical department, and a clinical trial. Equipped with an electronic medical record system and a database, patient information input from each clinical department terminal is stored in a server computer, and search terms converted from eligibility conditions and exclusion conditions of clinical trial information are stored in a clinical trial database.
- a clinical trial candidate screening system characterized by being able to search accumulated patient information using search terms and extract matching patients.
- This system is a system that can quickly extract clinical trial candidates by converting clinical trial information into search terms and searching for patient information.
- This system not only extracts clinical trial candidates, but also determines whether the eligibility and exclusion conditions for clinical trials that have been formulated are appropriate, analyzes adverse events of drugs after approval, and determines whether clinical trials are suitable for patients. It can also be used to search for presence or absence.
- FIG. 3 is a diagram showing the process of selecting clinical trial candidates within a medical institution according to the present embodiment.
- FIG. 1 is a diagram schematically showing a clinical trial candidate screening system of the present embodiment. The figure which shows the example of the item which inputs the medical information of this embodiment as structured information. ⁇ indicates items used for screening clinical trial candidates.
- 1 is a flowchart showing a process for confirming patient confirmation and consent matters according to the present embodiment. The figure which shows the clinical trial selection process suitable for the patient of this embodiment.
- the present invention relates to a method for selecting clinical trial candidates from patient information stored in a medical institution's database.
- a clinical trial is an intervention study conducted within the framework of clinical research.
- a clinical trial is a trial conducted for the purpose of obtaining approval from the Ministry of Health, Labor and Welfare as a drug, medical device, regenerative medicine product, etc. It is defined as.
- a clinical trial is a concept included in a clinical trial.
- the present invention is a method and system for quickly and labor-savingly screening a target patient group in clinical research, particularly in clinical trials and clinical trials. This is an effective system that can reduce the labor of doctors and clinical trial coordinators, as well as the cost and duration of clinical trials, especially in clinical trials that require a large number of candidates.
- this system can be used to quickly extract candidates.
- the present invention exhibits great effects by using a structured medical data integrated management database (Patent Document 6) that structures medical information in a medical institution and then integrates it for management and support.
- Data structuring is a data format that is represented in rows and columns, where each column has a specific meaning and the values in that column are selected from a particular selection or have a specified precision.
- a data format that is managed based on specific rules, such as entering numerical values.
- a collection of data items expressed as a combination of rows and columns has a unique meaning (e.g. basic patient information, pathological information, surgical information) and is managed separately from data with other meanings.
- Ru By structuring and linking data by category and condition, it is possible to understand the overall condition of a patient in a short time and to search for similar cases. If the data is unstructured, it is possible to extract matching patients by converting the eligibility and exclusion conditions so that they can be searched.
- FIG. 2 shows an outline of the screening process for clinical trial candidates of this embodiment.
- patient screening will be performed using a structured medical data integrated management database.
- the medical data structured as described above is called “structured medical data,” and the database that integrates and manages data such as tests, medical treatments, and admission/discharge records from each department within a medical institution is called an integrated management database. That's what it means.
- integrated management database even when simply referred to as an "integrated management database” herein, it has the same meaning as a structured medical care data integrated management database because patient information is stored as structured medical care data.
- Candidates for clinical trials are selected by checking the eligibility and exclusion conditions that are listed in the text. Since the eligibility conditions described in text cannot be searched in the database as they are, they are converted into searchable words, that is, words stored as structured data in the structured database (S101). . For example, in the case of a clinical trial targeting "patients with advanced solid cancers,” it is unlikely that patients with advanced solid cancers would be listed in their medical records. All you have to do is set cancers other than those as search terms. Furthermore, regarding "advanced” cancer, the search term "excluding T1/T2, N0", which is an early stage cancer, will be set.
- search term may be a disease stage classification such as TNM classification.
- TNM classification disease stage classification
- patient data is not stored as structured data, the words used when storing it as structured data may be used as search words.
- the conversion of eligibility conditions and exclusion conditions into search terms may be performed by any pharmaceutical company, CRO, or medical institution. However, the conversion into search terms must be performed by a person, such as a medical professional, who can convert them into medical expressions. Alternatively, search terms that can be candidates for natural language analysis by AI may be prepared in advance as a glossary, and the search terms may be automatically selected and presented from there.
- Patient search using the structured medical data integrated management database will be explained ( Figure 3).
- Pharmaceutical companies/CROs send clinical trial information, specifically eligibility and exclusion conditions, to a clinical trial database in order to select patients eligible for clinical trials.
- the eligibility conditions and exclusion conditions are converted into search terms that can be searched in the structured medical data integrated management database, that is, words stored as structured data, and patients who meet the conditions are selected.
- the structured medical data integrated management database connects structured information of medical institutions, specifically, structured information entered into electronic medical records and structured information entered in each clinical department. This is a database that stores information.
- patient information is managed using anonymized IDs.
- the server computer is equipped with an anonymized ID assigning means that automatically assigns an anonymized ID when a patient ID is registered at a reception desk, etc., and the patient's personal information is stored together with the patient ID as basic patient information and other information. is recorded in the server storage unit as extended patient information given an anonymized ID (see FIG. 4). Therefore, all selected patient information is anonymized.
- Anonymized IDs play an important role in protecting patients' personal information during clinical trials and trials.
- Information entered into electronic medical records is stored and synchronized in a data warehouse (DWH).
- DWH data warehouse
- the admission/discharge information includes anonymized ID, admission date/discharge date, admission department, reason for admission, and outcome information.
- the blood test information includes an anonymized ID, test items, and test results.
- the image diagnosis information includes an anonymized ID, a modality such as CT or MRI, and a diagnosis/finding.
- the pathological information includes anonymized ID, requesting department, pathological number, sampling date, site/material name, pathological tissue, and diagnosis/finding information.
- the somatic gene mutation information includes anonymized ID, gene, and mutation information.
- Data for each clinical department includes all information regarding diseases and treatments.
- the disease information includes information on anonymized ID, site, cancer stage (TNM stage), date of first diagnosis, date of confirmation of recurrence, date of last diagnosis, survival status, diagnosis status, and comorbidities.
- the treatment information includes anonymized ID, requesting medical department, treatment start date/end date, treatment target, procedure, pre-treatment PS, post-treatment PS, treatment result, and evaluation information. More specific treatment information is recorded as information regarding each treatment, such as surgery, immunotherapy, chemotherapy, and radiotherapy. Note that when newly registering disease information, an identifier (disease information identifier) for uniquely identifying each piece of data is automatically issued and managed.
- the detailed treatment information includes detailed information on surgery, detailed information on immunotherapy, detailed information on chemotherapy, detailed information on radiation therapy, and detailed information on integrated medicine.
- Detailed information on surgical procedures includes information on date of surgery/age at time of surgery, surgeon, operating time, amount of blood loss, number of lesions, infiltration status, lymph node dissection, resection/reconstruction, and postoperative complications, and is included in the treatment information in the database.
- the immunotherapy detailed information and chemotherapy detailed information includes information on treatment start/end dates, regimen name, number of courses conducted, and further includes information on drug, dosage, and age at administration, and treatment information in the database. is linked to.
- detailed radiation treatment information includes plan ID, plan start date/end date, treatment type, irradiation site, irradiation method, dose/number of doses, dose distribution, and age at plan start, and is included in the treatment information in the database.
- plan ID plan start date/end date
- treatment type irradiation site
- irradiation method dose/number of doses
- dose distribution and age at plan start
- Linked You can also select and enter information about how your cancer was discovered and your comorbidities. Since this information is stored in a structured manner, it is possible to perform highly accurate searches at high speed compared to general electronic medical record systems.
- medical care and treatment information such as symptoms, findings, test results, diagnoses, treatments, and prescriptions of patients visited by doctors and other medical personnel at medical institutions is stored by the patient's ID and information.
- each department manages a wide variety of data items and formats. Medical institutions typically store and protect electronic medical records for all patients. Additionally, descriptions of disease sites, symptoms, etc. may vary depending on the medical worker, which often hinders searches.
- each clinical department creates a database individually, and the format of stored data is not standardized.
- Daily medical records in general electronic medical record systems are stored in databases in natural language and are unstructured, which hinders the selection of clinical trial candidates.
- patient information is structured and anonymized IDs are assigned, so it is very advantageous for selecting patients suitable for clinical trials.
- Items marked with ⁇ in FIG. 4 are items that can be used in a search to select clinical trial candidates.
- information indicating that the cancer is advanced is indicated by the structured information of TNM classification and location in the "Disease Information" stage (TNM Stage) and location, respectively.
- TNM Stage Disease Information Stage
- Patient selection is easy because the information is stored as .
- whether a definitive diagnosis that is important for a clinical trial has been made can be determined by whether a pathological diagnosis is registered or not based on the presence or absence of a diagnosis/findings recorded in "pathology information.”
- pathology information patients who are considered to be alive at the time of the search, for example, patients who have visited the hospital within one year, can be selected based on the survival status of "disease information" and the last confirmed date of "extended patient information" with the patient's consent. For patients who are 18 years of age or older and can be eligible for treatment, this information can be obtained from the date of birth information in the "Basic Patient Information.”
- the patients who have been screened according to the eligibility conditions and exclusion conditions are judged by the doctor and clinical trial coordinator as to whether they are eligible as clinical trial candidates (FIG. 2, S103). Since patient screening is performed in advance, the attending physician or clinical trial coordinator only has to confirm that each patient is eligible as a clinical trial candidate, and candidates can be selected with little effort.
- patient information is anonymized as mentioned above, and it is possible to perform searches with the anonymized ID, allowing patients to be selected while maintaining anonymity. Can be done.
- pharmaceutical companies need to set appropriate eligibility and exclusion conditions in order to collect the necessary number of patients for the trial. Since it is possible to determine in advance how many clinical trial candidates a medical institution has based on the eligibility and exclusion conditions that have been set, it is possible to set appropriate conditions and use this to formulate clinical trial plans.
- the structured medical care data integrated management database when staff access patient information from within a medical institution, it is possible to display the patient ID and name. Therefore, it is possible to explain the clinical trial to patients, obtain written consent, etc. smoothly.
- access from outside the medical institution can be determined based on the IP address and communication packet route, so access from outside the medical institution or even within the medical institution to the structured medical data integrated management database. It can be set so that only the anonymized ID is displayed to employees such as CROs who do not have access authority.
- this system is equipped with an interface and repository that complies with the medical information standardization standard HL7 FHIR (Fast Health Interoperable Resources), and is capable of online communication with systems outside medical institutions such as CROs and pharmaceutical companies, as well as various systems within medical institutions. Built to work together offline. Therefore, the exchange of clinical trial information can be carried out smoothly.
- HL7 FHIR Fest Health Interoperable Resources
- information such as pathological information and test information from a department other than the treating doctor may be stored in a database separate from the electronic medical record system.
- a database separates the electronic medical record system.
- the doctor provides an explanation to the patients selected as clinical trial candidates, and provides consent for the trial, consent to perform a biopsy during the trial, and consent to provide specimens obtained from the biopsy. It is necessary to obtain and record it (FIG. 2, S104). Only after this consent is obtained can a person be registered as a clinical trial subject.
- an electronic consent form that can be signed electronically to confirm the consent items, it is possible to prevent omissions in the consent boxes and omissions in explanations. Furthermore, if explanations and consent can be provided via the Web, registration for clinical trials becomes possible even when clinical trial candidates are located in remote locations.
- the patient operates the terminal to check each consent box to indicate consent. If there are any items that have not been checked, a message indicating that the check has been omitted will be displayed on the operating terminal, so there is no need to worry about leaking any items that should be checked. If all items are confirmed, the applicant will be registered as a clinical trial candidate.
- patient monitoring which is the most important task during clinical trials, can also be performed via the Web.
- patient monitoring which is the most important task during clinical trials, can also be performed via the Web.
- this system information and data obtained when clinical trial subjects participating remotely undergo post-medication monitoring it is possible to efficiently collect the information and data as a monitoring data set during the clinical trial.
- Synthetic Control Arm is a clinical trial design that has recently been proposed as a clinical trial design option that does not require a control group of subjects or can reduce the number of subjects.
- the control group for the therapeutic agent/method being tested is the standard treatment.
- SCA patients who have received standard treatment for the same indication in the past are selected as targets.
- patients who have received standard treatment for the same indication in the past are selected as targets.
- patients who have received standard treatment for the same indication in the past are selected as targets.
- patients who have received standard treatment for the same indication in the past are selected as targets.
- patients who have received standard treatment for the same indication in the past are selected as targets.
- patients who have received standard treatment for the same indication in the past are selected as targets.
- patients who have received standard treatment for the same indication in the past are selected as targets.
- patients who have received standard treatment for the same indication in the past are selected as targets.
- Whether a definitive diagnosis has been made is determined by the presence or absence of pathological diagnosis registration and the presence or absence of diagnosis/findings in "pathology information”, and if it is an advanced solid cancer,
- events that are not recorded as test values such as adverse events such as diarrhea, hand-foot syndrome, and numbness
- adverse events can also be extracted by being recorded in a structured manner. If adverse events can be extracted, it will also be possible to identify patient groups at high risk for specific adverse events, making it possible to use medicines more safely.
- this system determines the eligibility and exclusion conditions necessary to formulate a clinical trial implementation plan, screens patients who are suitable for clinical trials, examines adverse events, and searches for clinical trials suitable for patients. It is also a system that can be used quickly. Furthermore, the embodiments described above are merely examples, and it goes without saying that various changes, combinations of embodiments, omissions, etc. can be made without departing from the gist of the invention.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024529003A JPWO2023248978A1 (cg-RX-API-DMAC7.html) | 2022-06-21 | 2023-06-19 | |
| EP23827161.3A EP4535365A4 (en) | 2022-06-21 | 2023-06-19 | METHOD AND SYSTEM FOR CLINICAL TRIAL SUPPORT |
| US18/877,477 US20250378922A1 (en) | 2022-06-21 | 2023-06-19 | Clinical trial assistance method and clinical trial assistance system |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022-099352 | 2022-06-21 | ||
| JP2022099352 | 2022-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023248978A1 true WO2023248978A1 (ja) | 2023-12-28 |
Family
ID=89380015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2023/022600 Ceased WO2023248978A1 (ja) | 2022-06-21 | 2023-06-19 | 臨床試験支援方法、及び臨床試験支援システム |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250378922A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4535365A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023248978A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023248978A1 (cg-RX-API-DMAC7.html) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7660249B1 (ja) * | 2024-08-06 | 2025-04-10 | 亜紗子 小倉 | 情報処理システム、情報処理方法およびコンピュータプログラム |
| CN119851839A (zh) * | 2025-03-21 | 2025-04-18 | 北京大学 | 基于试验数据的治疗敏感人群筛选方法、系统、设备及存储介质 |
| WO2025154192A1 (ja) * | 2024-01-17 | 2025-07-24 | 日本電気株式会社 | 選定支援装置、選定支援方法および記録媒体 |
| JP7895599B1 (ja) * | 2025-12-05 | 2026-07-28 | 株式会社日本ブレーン | 臨床研究支援装置、臨床研究支援方法、及び、臨床研究支援プログラム |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002183320A (ja) | 2000-12-15 | 2002-06-28 | Moss Institute Co Ltd | 臨床試験のための被験者登録システム |
| JP2014052821A (ja) * | 2012-09-06 | 2014-03-20 | Mebix Kk | 電子カルテスクリーニングシステム、電子カルテスクリーニング装置、電子カルテスクリーニング方法及び電子カルテスクリーニングプログラム |
| JP2016024663A (ja) | 2014-07-22 | 2016-02-08 | 株式会社メディカルフロント | 治験適合患者選択装置、システム及び方法 |
| JP2019133540A (ja) | 2018-02-02 | 2019-08-08 | 公益財団法人がん研究会 | 構造化診療データ統合管理データベースを用いた匿名化医療情報検索支援システム |
| JP2021111248A (ja) | 2020-01-15 | 2021-08-02 | キヤノンメディカルシステムズ株式会社 | 治験マッチング装置 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001093178A2 (en) * | 2000-05-31 | 2001-12-06 | Fasttrack Systems, Inc. | Clinical trials management system and method |
| MX2016007389A (es) * | 2013-12-09 | 2017-04-27 | Trinetx Inc | Identificacion de candidatos para ensayos clinicos. |
| GB201506824D0 (en) * | 2015-04-22 | 2015-06-03 | Trailreach Ltd | TrailReach Multitrial |
| US10878010B2 (en) * | 2015-10-19 | 2020-12-29 | Intelligent Medical Objects, Inc. | System and method for clinical trial candidate matching |
| WO2019068870A1 (en) * | 2017-10-06 | 2019-04-11 | Koninklijke Philips N.V. | METHODS AND SYSTEMS FOR CLINICAL HEALTH CARE TRIALS |
| US20200381087A1 (en) * | 2019-05-31 | 2020-12-03 | Tempus Labs | Systems and methods of clinical trial evaluation |
| US11705226B2 (en) * | 2019-09-19 | 2023-07-18 | Tempus Labs, Inc. | Data based cancer research and treatment systems and methods |
-
2023
- 2023-06-19 JP JP2024529003A patent/JPWO2023248978A1/ja active Pending
- 2023-06-19 WO PCT/JP2023/022600 patent/WO2023248978A1/ja not_active Ceased
- 2023-06-19 EP EP23827161.3A patent/EP4535365A4/en active Pending
- 2023-06-19 US US18/877,477 patent/US20250378922A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002183320A (ja) | 2000-12-15 | 2002-06-28 | Moss Institute Co Ltd | 臨床試験のための被験者登録システム |
| JP2014052821A (ja) * | 2012-09-06 | 2014-03-20 | Mebix Kk | 電子カルテスクリーニングシステム、電子カルテスクリーニング装置、電子カルテスクリーニング方法及び電子カルテスクリーニングプログラム |
| JP2016024663A (ja) | 2014-07-22 | 2016-02-08 | 株式会社メディカルフロント | 治験適合患者選択装置、システム及び方法 |
| JP2019133540A (ja) | 2018-02-02 | 2019-08-08 | 公益財団法人がん研究会 | 構造化診療データ統合管理データベースを用いた匿名化医療情報検索支援システム |
| JP2021111248A (ja) | 2020-01-15 | 2021-08-02 | キヤノンメディカルシステムズ株式会社 | 治験マッチング装置 |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP4535365A4 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025154192A1 (ja) * | 2024-01-17 | 2025-07-24 | 日本電気株式会社 | 選定支援装置、選定支援方法および記録媒体 |
| JP7660249B1 (ja) * | 2024-08-06 | 2025-04-10 | 亜紗子 小倉 | 情報処理システム、情報処理方法およびコンピュータプログラム |
| JP2026027931A (ja) * | 2024-08-06 | 2026-02-19 | 亜紗子 小倉 | 情報処理システム、情報処理方法およびコンピュータプログラム |
| CN119851839A (zh) * | 2025-03-21 | 2025-04-18 | 北京大学 | 基于试验数据的治疗敏感人群筛选方法、系统、设备及存储介质 |
| JP7895599B1 (ja) * | 2025-12-05 | 2026-07-28 | 株式会社日本ブレーン | 臨床研究支援装置、臨床研究支援方法、及び、臨床研究支援プログラム |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4535365A1 (en) | 2025-04-09 |
| JPWO2023248978A1 (cg-RX-API-DMAC7.html) | 2023-12-28 |
| US20250378922A1 (en) | 2025-12-11 |
| EP4535365A4 (en) | 2026-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6588584B2 (ja) | 構造化診療データ統合管理データベースを用いた匿名化医療情報検索支援システム | |
| US8036915B2 (en) | System and method for collecting and managing patient data | |
| US20250378922A1 (en) | Clinical trial assistance method and clinical trial assistance system | |
| Pérol et al. | The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME) | |
| Melzer et al. | Leveraging real-world data for the selection of relevant eligibility criteria for the implementation of electronic recruitment support in clinical trials | |
| Lin et al. | Development and implementation of a dynamically updated big data intelligence platform from electronic health records for nasopharyngeal carcinoma research | |
| US7742933B1 (en) | Method and system for maintaining HIPAA patient privacy requirements during auditing of electronic patient medical records | |
| Barron et al. | The Healthcare Integrated Research Database (HIRD) as a Real‐World Data Source for Pharmacoepidemiologic Research | |
| Ng et al. | Concordance of a decision algorithm and multidisciplinary team meetings for patients with liver cancer—a study protocol for a randomized controlled trial | |
| Richard et al. | A methodology for identifying behavioral health advanced practice registered nurses in administrative claims | |
| Vyas et al. | Systematic review of the use of the Dermatology Life Quality Index in routine clinical practice: evidence from 287 articles across 56 countries | |
| Kahl et al. | Digital technologies in hereditary coagulation disorders: a systematic review | |
| Rao et al. | Streamlining the quantitative metrics workflow at a comprehensive cancer center | |
| McGrath et al. | Use of participant data and biological samples is insufficiently described in participant information leaflets | |
| Va et al. | Creation of the first french database in primary care using the icpc2: Feasibility study | |
| Hau et al. | A centralized EHR-Based model for the recruitment of rural and lower socioeconomic participants in pragmatic trials: A secondary analysis of the diuretic comparison project | |
| Beltran et al. | Computational phenotyping within electronic healthcare data to identify transgender people in the United States: a narrative review | |
| WO2022244829A1 (ja) | 生体情報管理システム、生体情報管理方法、及び生体情報管理プログラム | |
| Chen et al. | Construction and application of nasopharyngeal carcinoma-specific big data platform based on electronic health records | |
| Hayakawa et al. | Benzodiazepine-related dementia risks and protopathic biases revealed by multiple-kernel learning with electronic medical records | |
| Tipre et al. | Integration of sexual orientation and gender identity data into a comprehensive cancer center tumor registry: challenges and lessons learned | |
| Mead et al. | Fluoxetine and fractures after stroke: An individual patient data meta-analysis of three large randomized controlled trials of fluoxetine for stroke recovery | |
| Barbic | PROSPERO International prospective register of systematic reviews | |
| Nakashima | Epidemiologic research on real-world medical data in Japan | |
| Ascha et al. | A single center review of COVID-19 testing and vaccination in the transgender and nonbinary population |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23827161 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024529003 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18877477 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023827161 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2023827161 Country of ref document: EP Effective date: 20250102 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWP | Wipo information: published in national office |
Ref document number: 2023827161 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 18877477 Country of ref document: US |